Arbovax

Arbovax is engaged in the development of vaccines for protection against mosquito-borne diseases that collectively infect over 300 million people annually.  Mosquito-borne viruses provide some of the most important examples of emerging and resurging diseases of global significance including Dengue Fever, Japanese Encephalitis, West Nile and Yellow Fever; the market for an effective Dengue virus vaccine alone is in excess of $2.0 billion. Several of the Alphavirus families of diseases, such as Venezuelan Equine Encephalitis, are now on the bioterrorism watch list.  Chikungunya, also an Alphavirus, was considered a disease primarily confined to Southern India. By 2014 Chikungunya had exhibited an expansion of territory with over 1200 infections in North America now.